Downward price pressures on Tenaya Therapeutics (TNYA) stock stem from the severe volatility, cash burn pressures, and risk-averse market sentiment that typically impact clinical-stage biotechnology and micro-cap healthcare equities. Because early-stage biopharmaceutical companies rely heavily on continuous capital raises, debt-free operational funding, and successful clinical trial milestones before achieving commercial product revenues, any macro-biotech sector downturns or delays in pipeline updates frequently trigger sharp valuation corrections and sell-offs among risk-focused retail and institutional investors.